Johnson & Johnson (J&J) recently announced it has entered into a definitive agreement to acquire Atraverse Medical—a company attempting to pioneer next-generation left-heart access and radiofrequency (RF) technologies.
Achieving safe and precise access to the left atrium remains “one of the most critical steps” in atrial fibrillation (AF) ablation, as noted in a J&J press release.
Atraverse’s Hotwire transseptal access system—already used in nearly 3,000 clinical procedures—is a US Food and Drug Administration (FDA)-cleared RF guidewire and generator system designed for “greater confidence and control” when accessing the left atrium. The system offers multiple innovative features—including impedance-sensing automatic energy shutoff, compatibility with multiple sheaths, and clear tip visibility under intracardiac echocardiography—that support smooth and efficient access to the left atrium, the release adds.
Additionally, the release notes that the planned acquisition of Atraverse would strengthen J&J’s portfolio of cardiac ablation solutions, providing electrophysiologists with innovative tools to treat patients with AF and other cardiac arrhythmias.
The transaction is expected to close in the second quarter of 2026, subject to customary closing conditions. Financial terms of the transaction are not being disclosed.
